Investor Overview

Webcast ImageWebcast
Verastem Inc at Stifel Nicolaus 2017 Healthcare Conference (Replay)
11/14/17 at 10:15 a.m. ET
Verastem Inc at Stifel Nicolaus 2017 Healthcare Conference
Tuesday, November 14, 2017 10:15 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Webcast ImageWebcast
Verastem Inc at Jefferies 2017 London Healthcare Conference (Replay)
11/16/17 at 5:20 p.m. GMT
Verastem Inc at Jefferies 2017 London Healthcare Conference
Thursday, November 16, 2017 5:20 p.m. GMT  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Corporate Profile
Verastem, Inc. (NASDAQ:VSTM) is a biopharmaceutical company focused on discovering and developing drugs to improve outcomes for patients with cancer. Verastem’s product candidates seek to treat cancer by targeting malignant cells both directly and through modulation of the tumor microenvironment. The Company is currently developing duvelisib, a dual inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, which has successfully met its primary endpoint in a Phase 3 registration trial in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and a Phase 2 study in refractory indolent Non-Hodgkin’s Lymphoma (iNHL). Verastem plans to share these clinical data with the U.S. Food and Drug Administration (FDA) with the goal of filing a New Drug Application (NDA) with the FDA during the first half of 2018. Other clinical product candidates include focal adhesion kinase (FAK) inhibitors defactinib. Defactinib is currently being evaluated in three separate clinical collaborations in combination with immunotherapeutic agents for the treatment of several different cancer types, including pancreatic, ovarian and non-small cell lung cancer, and mesothelioma.
Stock Quote
VSTM (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$3.43
Change (%) Stock is Down 0.03 (0.87%)
Volume173,194
Data as of 11/17/17 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent News More >>
DateTitle 
11/08/17Verastem to Present at Upcoming Investor Conferences
BOSTON--(BUSINESS WIRE)--Nov. 8, 2017-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today announced that the Company will present at the following upcoming investor conferences: The Stifel Nicolaus 2017 Healthcare Conference on Tuesday, November 14, at 10:15 a.m. ET in New York City, NY, USA The Jefferies 2017 London ... 
Printer Friendly Version
11/07/17Verastem Reports Third Quarter 2017 Financial Results
BOSTON--(BUSINESS WIRE)--Nov. 7, 2017-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today reported financial results for the third quarter ended September 30, 2017 and provided an overview of certain corporate developments and plans. “The third quarter was a pivotal time for Verastem with the announcement of positive top-line data from the pivotal... 
Printer Friendly Version
11/01/17Verastem Announces Data from Phase 3 DUO Study Selected for Oral Presentation at the American Society of Hematology 2017 Annual Meeting
Four Abstracts Selected, Including Two Oral Presentations BOSTON--(BUSINESS WIRE)--Nov. 1, 2017-- Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today announced that four abstracts have been selected for presentation, including two oral presentations, at the upcoming American Society of Hematology (ASH) 2017 Annual Meeting being held December 9-12, 2017 in ... 
Printer Friendly Version
10/31/17Verastem Announces Regulatory Strategy for Duvelisib New Drug Application Following Guidance from FDA
Company Plans to Submit a Single NDA Requesting Full Approval of Duvelisib for the Treatment of Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Accelerated Approval for the Treatment of Patients with Relapsed or Refractory Follicular Lymphoma Company Plans to Submit NDA for Duvelisib During First Quarter of 2018 BOSTON--(BUSINESS WIRE)--Oct. 31, 2017-- Verastem, Inc. (NASDAQ: VSTM), focu... 
Printer Friendly Version
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Verastem Inc posts new information to the site. Just enter your e-mail address and click Submit.
 

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.